Fig. 2 | British Journal of Cancer

Fig. 2

From: Platinum response characteristics of patients with pancreatic ductal adenocarcinoma and a germline BRCA1, BRCA2 or PALB2 mutation

Fig. 2

Real World Progression Free Survival. a The rwPFS was 10.1 months in the mut-positive cohort as compared to 6.9 months in the control cohort (HR 0.43; 95% CI 0.25–0.74; p = 0.0068). b A subset analysis comparing rwPFS with platinum use, by line of therapy. The rwPFS of mut-positive patients who received platinum-based chemotherapy in the first-line setting was 21.2 months as compared to 7.9 months for control patients treated with platinum in the first-line setting (p = 0.0046) and 2.5 months for mut-positive patients treated with platinum in the second-line setting (p = 0.0001). Kaplan-Meier methodology was used to estimate rwPFS. The hazard ratio was estimated by means of the log-rank test

Back to article page